Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ligelizumab - IgE inhibitor Study Indication Phase NCT02649218 (CQGE031C2201E1) Chronic spontaneous urticaria / Chronic idiopathic urticaria Phase 2 Patients 226 Long-term safety; number of participants with treatment-emergent adverse events NCT03580356 Pearl 2 (CQGE031C2303) Chronic spontaneous urticarial / Chronic idiopathic urticaria? Phase 3 1050 Absolute change from baseline in UAS7 (Urticaria Activity Score) at week 12 Primary Outcome Measures Arms Intervention Target Patients Ligelizumab 240 mg q4wks open label for 52 weeks Adult patients with chronic spontaneous urticaria inadequately controlled with H1- antihistamines at approved or increased doses, alone or in combination with H2- antihistamines or leukotriene receptor antagonists. Ligelizumab dose A q4w for 52 weeks Ligelizumab dose B q4w for 52 weeks Omalizumab 300 mg q4w for 52 weeks Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria inadequately controlled with H1-antihistamines Read-out Milesstone(s) 2019 (actual) Publication 82 Investor Relations | Q3 2021 Results Manuscript: Primary results extension trial (Allergy), H2 2021 H2-2021 (Q4/2021-Q1/2022 potential COVID impact) Past publications: Study design presented at UCARE 2018 Congress: primary results EADV 2022 (H2 2022) or AAAAI 2023 Manuscript: primary results, Journal (TBD), 2023 1 NOVARTIS | Reimagining Medicine

View entire presentation